Form 4: BVF Partners and Affiliates Report Beneficial Ownership Changes in Kymera Therapeutics

BVF Partners L.P. and its affiliates reported changes in their beneficial ownership of Kymera Therapeutics, Inc. common stock and pre-funded warrants.

Summary

• BVF Partners L.P., along with several affiliated entities and Mark N. Lampert, jointly filed a Form 4 detailing changes in beneficial ownership of Kymera Therapeutics, Inc. securities.
• The report covers common stock and pre-funded warrants to purchase common stock.
• The transactions occurred on August 20, 2024.
• The reporting persons include Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert.
• Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.
• The filing indicates the ownership structure and relationships between the various entities, clarifying how beneficial ownership is attributed.
• Gorjan Hrustanovic, a member of Partners and a director of Kymera Therapeutics, has an agreement to transfer any economic benefit from the sale of shares issuable upon exercise of certain securities to Partners.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting changes in ownership. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Key Dates